Nevertheless, future studies are warranted to validate these findings and to clinically assess the potential use of PARP1 inhibitors in high-risk patients to ameliorate ALL response to chemotherapy and prevent patients’ relapse. Here, PARP1 is linked to acute lymphoblastic leukemia.